Mendota Financial Group LLC Buys 76 Shares of Quest Diagnostics Incorporated (NYSE:DGX)

Mendota Financial Group LLC increased its position in shares of Quest Diagnostics Incorporated (NYSE:DGXFree Report) by 6.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,296 shares of the medical research company’s stock after buying an additional 76 shares during the quarter. Mendota Financial Group LLC’s holdings in Quest Diagnostics were worth $179,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Kentucky Retirement Systems Insurance Trust Fund acquired a new position in shares of Quest Diagnostics during the third quarter worth approximately $493,000. CHURCHILL MANAGEMENT Corp acquired a new position in Quest Diagnostics during the fourth quarter worth $1,483,000. Wellington Management Group LLP grew its holdings in shares of Quest Diagnostics by 14.6% during the third quarter. Wellington Management Group LLP now owns 2,613,793 shares of the medical research company’s stock valued at $318,517,000 after buying an additional 333,947 shares during the last quarter. Pacer Advisors Inc. increased its position in shares of Quest Diagnostics by 201.5% during the fourth quarter. Pacer Advisors Inc. now owns 31,912 shares of the medical research company’s stock worth $4,400,000 after acquiring an additional 21,327 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV raised its holdings in shares of Quest Diagnostics by 1.3% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 16,439 shares of the medical research company’s stock worth $2,003,000 after acquiring an additional 218 shares during the last quarter. Institutional investors own 88.06% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Michael E. Prevoznik sold 5,611 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $125.88, for a total transaction of $706,312.68. Following the sale, the senior vice president now directly owns 38,478 shares in the company, valued at approximately $4,843,610.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, SVP Michael E. Prevoznik sold 661 shares of the company’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $126.14, for a total transaction of $83,378.54. Following the sale, the senior vice president now directly owns 40,206 shares in the company, valued at $5,071,584.84. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Michael E. Prevoznik sold 5,611 shares of the firm’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $125.88, for a total transaction of $706,312.68. Following the completion of the transaction, the senior vice president now owns 38,478 shares of the company’s stock, valued at $4,843,610.64. The disclosure for this sale can be found here. Insiders sold 15,150 shares of company stock worth $1,913,202 over the last quarter. 1.70% of the stock is currently owned by company insiders.

Quest Diagnostics Stock Up 1.6 %

Quest Diagnostics stock opened at $133.11 on Friday. The company has a quick ratio of 1.20, a current ratio of 1.31 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $14.78 billion, a P/E ratio of 17.77, a P/E/G ratio of 2.87 and a beta of 0.90. The firm has a 50 day moving average price of $127.64 and a 200-day moving average price of $130.23. Quest Diagnostics Incorporated has a twelve month low of $119.59 and a twelve month high of $148.62.

Quest Diagnostics (NYSE:DGXGet Free Report) last released its earnings results on Thursday, February 1st. The medical research company reported $2.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.11 by $0.04. Quest Diagnostics had a return on equity of 15.79% and a net margin of 9.23%. The business had revenue of $2.29 billion during the quarter, compared to the consensus estimate of $2.25 billion. During the same period last year, the business posted $1.98 earnings per share. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. As a group, equities analysts predict that Quest Diagnostics Incorporated will post 8.75 EPS for the current year.

Quest Diagnostics Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 22nd. Shareholders of record on Monday, April 8th will be issued a dividend of $0.75 per share. The ex-dividend date is Friday, April 5th. This is an increase from Quest Diagnostics’s previous quarterly dividend of $0.71. This represents a $3.00 annualized dividend and a yield of 2.25%. Quest Diagnostics’s dividend payout ratio is 37.92%.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Bank of America upgraded Quest Diagnostics from a “neutral” rating to a “buy” rating and lifted their price target for the company from $140.00 to $160.00 in a research note on Tuesday, December 12th. Leerink Partnrs reiterated a “market perform” rating on shares of Quest Diagnostics in a report on Monday, February 26th. TheStreet cut Quest Diagnostics from a “b-” rating to a “c” rating in a research note on Monday, February 5th. StockNews.com lowered shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Thursday, February 1st. Finally, Truist Financial restated a “hold” rating and set a $145.00 price target on shares of Quest Diagnostics in a report on Wednesday, March 20th. Ten research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Quest Diagnostics currently has a consensus rating of “Hold” and a consensus target price of $144.18.

Get Our Latest Report on DGX

Quest Diagnostics Company Profile

(Free Report)

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

See Also

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGXFree Report).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.